van der Gaast A - Search Results

1

Prognostic factors for survival in patients with advanced oesophageal cancer treated with cisplatin-based combination chemotherapy.

Polee MB, Hop WC, Kok TC, Eskens FA, van der Burg ME, Splinter TA, Siersema PD, Tilanus HW, Stoter G, van der Gaast A. Polee MB, et al. Among authors: van der gaast a, van der burg me. Br J Cancer. 2003 Dec 1;89(11):2045-50. doi: 10.1038/sj.bjc.6601364. Br J Cancer. 2003. PMID: 14647136 Free PMC article.

2

Teniposide (VM-26) in ovarian cancer: a review.

van der Gaast A, Splinter TA. van der Gaast A, et al. Semin Oncol. 1992 Apr;19(2 Suppl 6):95-7. Semin Oncol. 1992. PMID: 1411643 Review.

3

Prognostic value of serum thymidine kinase, tissue polypeptide antigen and neuron specific enolase in patients with small cell lung cancer.

van der Gaast A, van Putten WL, Oosterom R, Cozijnsen M, Hoekstra R, Splinter TA. van der Gaast A, et al. Among authors: van putten wl. Br J Cancer. 1991 Aug;64(2):369-72. doi: 10.1038/bjc.1991.309. Br J Cancer. 1991. PMID: 1654076 Free PMC article.

4

Chemotherapy as treatment of choice in extrapulmonary undifferentiated small cell carcinomas.

Van Der Gaast A, Verwey J, Prins E, Splinter TA. Van Der Gaast A, et al. Cancer. 1990 Feb 1;65(3):422-4. doi: 10.1002/1097-0142(19900201)65:3<422::aid-cncr2820650308>3.0.co;2-y. Cancer. 1990. PMID: 1688727

5

Ifosfamide in advanced adenocarcinoma of the oesophagus or oesophageal-gastric junction area. Rotterdam Esophageal Tumor Study Group.

Kok TC, van der Gaast A, Splinter TA, Tilanus HW. Kok TC, et al. Among authors: van der gaast a. Eur J Cancer. 1991;27(9):1112-4. doi: 10.1016/0277-5379(91)90305-w. Eur J Cancer. 1991. PMID: 1835618

6

Evaluation of CA19-9 serum levels for monitoring disease activity during chemotherapy of pancreatic adenocarcinoma.

Bac DJ, Kok TC, van der Gaast A, Splinter TA. Bac DJ, et al. Among authors: van der gaast a. J Cancer Res Clin Oncol. 1991;117(3):263-5. doi: 10.1007/BF01625436. J Cancer Res Clin Oncol. 1991. PMID: 2033095

7

5-Fluorouracil, doxorubicin and mitomycin C (FAM) combination chemotherapy for metastatic adenocarcinoma of unknown primary.

van der Gaast A, Verweij J, Planting AS, Stoter G. van der Gaast A, et al. Eur J Cancer Clin Oncol. 1988 Apr;24(4):765-8. doi: 10.1016/0277-5379(88)90312-4. Eur J Cancer Clin Oncol. 1988. PMID: 3383976

8

Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1.

van der Gaast A, Schoenmakers CH, Kok TC, Blijenberg BG, Cornillie F, Splinter TA. van der Gaast A, et al. Br J Cancer. 1994 Mar;69(3):525-8. doi: 10.1038/bjc.1994.95. Br J Cancer. 1994. PMID: 7510117 Free PMC article.

9

Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site.

van der Gaast A, Verweij J, Planting AS, Hop WC, Stoter G. van der Gaast A, et al. J Clin Oncol. 1995 Jul;13(7):1720-5. doi: 10.1200/JCO.1995.13.7.1720. J Clin Oncol. 1995. PMID: 7541451 Clinical Trial.

10

Prognostic significance of tissue polypeptide-specific antigen (TPS) in patients with advanced non-small cell lung cancer.

van der Gaast A, Schoenmakers CH, Kok TC, Blijenberg BG, Hop WC, Splinter TA. van der Gaast A, et al. Eur J Cancer. 1994;30A(12):1783-6. doi: 10.1016/0959-8049(94)00214-p. Eur J Cancer. 1994. PMID: 7880606

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

136 results

Search Page

Filters